Pfizer Inc.

New York, Washington D.C.
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Pfizer scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Pfizer increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Pfizer forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Pfizer has used its political contributions to advance ideological causes, groups, and policies. The company is a signatory of the Gender & Diversity KPI Alliance chairman and its CEO signed Catalyst's Champions for Change pledge. Pfizer is a platinum partner of the Human Rights Campaign (HRC), funds Planned Parenthood, and multiple LGBTQ organizations. The company supports the Equality Act and its leadership has been outspoken on topics such as transgender activism. Pfizer's CEO is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism. Pfizer partially funds HRC's Healthcare Equality Index. The company opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. Pfizer signed the Health Sector Climate Pledge, committing itself to achieve net zero emissions by 2050. The company is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. For these reasons, Pfizer receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of Pfizer Inc.

Albert Bourla DVM Ph.D.

Albert Bourla DVM Ph.D.


Headquartered in New York, Washington D.C., Pfizer Inc. is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Albert Bourla DVM Ph.D. and Albert Bourla DVM Ph.D. serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $259,800 to Republican causes and $1,344,974 to Democratic causes. Under their tenure, Pfizer Inc. currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:





Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
4/27/23GovernanceKenneth SteinerIndependent Board ChairAgainst34.52%
4/27/23SocialTrinity HealthReport on Impact of Extended Patent Exclusivities on Product AccessAgainst29.67%
4/27/23GovernanceTara Health FoundationReport on Congruency of Political ContributionsAgainst13.88%
4/27/23SocialOxfam AmericaFeasibility Report for Transfer of Intellectual Properties to Potential COVID-19 vaccine manufacturersAgainst11.99%
4/27/23GovernanceJohn CheveddenRatification of Termination PayAgainst9.90%
4/28/22GovernanceSisters of St. FrancisReport on Board Oversight of Risks Related to Anticompetitive PracticesAgainst30.45%
4/28/22GovernanceJohn CheveddenAmend Proxy Access RightAgainst28.98%
4/28/22SocialOxfam America, Inc.Report on Feasibility of Technology Transfer to Boost COVID-19 Vaccine ProductionAgainst27.37%
4/28/22SocialNational Center for Public Policy ResearchReport on Congruency of Political Election Expenditures with Company Values and PoliciesAgainst10.41%
4/28/22SocialThe Shareholder CommonsReport on Public Health Costs of Limited Sharing of Vaccine TechnologyAgainst8.71%
Generate Reports